

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)



(10) International Publication Number
WO 2025/171303 A1

(51) International Patent Classification:

C07C 13/20 (2006.01) A61K 31/14 (2006.01)
A61K 31/203 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2025/015071

(22) International Filing Date:

07 February 2025 (07.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/551,150 08 February 2024 (08.02.2024) US

(71) Applicants: MASTERY BIOTECH CO., LTD. [CN/CN];

3 F., No. 51, Shitan Rd., Neihu Dist., Taipei City, 114057 (TW). SHIH, Min-Yi [US/US]; 718 N Lucia Ave. B, Redondo Beach, California 90277 (US).

(72) Inventor: LIN, Bo-Lin; 3 F., No. 51, Shitan Rd., Neihu

Dist., Taipei City, 114057 (TW).

(74) Agent: KUNG, Viola et al.; P.O. Box 1247, Seattle, Washington 98111-1247 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: CONJUGATE COMPOUND COMPRISING 9-CIS-RETINOIC ACID AND MONOSACCHARIDE




FIG. 4

(57) Abstract: The present disclosure provides a conjugate compound comprising 9-cis-retinoic acid and a monosaccharide, and the pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. The present compound is useful in treating cancers or viral infections.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*